Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.

ABSTRACT: The rat parvovirus H-1PV is a promising anticancer agent given its oncosuppressive properties and the absence of known side effects in humans. H-1PV replicates preferentially in transformed cells, but the virus can enter both normal and cancer cells. Uptake by normal cells sequesters a significant portion of the administered viral dose away from the tumor target. Hence, targeting H-1PV entry specifically to tumor cells is important to increase the efficacy of parvovirus-based treatments. In this study, we first found that sialic acid plays a key role in H-1PV entry. We then genetically engineered the H-1PV capsid to improve its affinity for human tumor cells. By analogy with the resolved crystal structure of the closely related parvovirus minute virus of mice, we developed an in silico thr

SUBMITTER: Allaume X 

PROVIDER: S-EPMC3302485 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature